YHYanjie Hao

Yanjie Hao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanjie Hao has a total of 295 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Measurement of kidney disease in a novel multidomain treatment response measure for SLE clinical trials

    by Kathryn Connelly, Eric F Morand, Rachel Koelmeyer, Lavanya Rajagopala, Arushi Ramnarain, Fabien Vincent, Yanjie Hao, Ambika Wakhlu, Katie Liao, Darshini Ayton, et al.

  • Longitudinal Comparison of Treat-to-Target States and Clinical Outcomes in Patients With Late-Onset Versus Early-Onset Systemic Lupus Erythematosus

    by Worawit Louthrenoo, Alberta Hoi, Vera Golder, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue-Fen Luo, Yeong-Jian Jan Wu, Sandra V. Navarra, et al.

    Objective: We compared demographic and clinical characteristics between patients with late-onset (LO) and early-onset (EO) systemic lupus erythematosus (SLE) and examined their longitudinal associations with treatment targets and long-term outcomes, irreversible organ damage accrual, and health-related quality of life (HRQOL). Methods: We analyzed prospectively collected data from patients enrolled in the Asia Pacific Lupus Collaboration cohort. Patients diagnosed with SLE at age > 50 years were classified as having LO-SLE, whereas those diagnosed at age ≤ 50 years were classified as having EO-SLE. Longitudinal associations with treatment targets (Low Lupus Disease Activity State [LLDAS] and Definition of Remission in SLE [DORIS] remission), organ damage accrual (Systemic Lupus International Collaborating Clinics/American College of Rheumatology [SLICC/ACR] Damage Index), and HRQOL (36-item Short Form Health Survey v2 physical and mental component summary [PCS and MCS] scores) were examined using multivariable multilevel logistic, recurrent event survival, and linear mixed-effects models, respectively. Disease activity, flares, medication exposure, and other clinical characteristics were also compared between groups. Results: Among 3917 patients studied, 346 (8.8%) had LO-SLE and 3571 (91.2%) had EO-SLE. Compared to patients with EO-SLE, those with LO-SLE had lower disease activity, lower glucocorticoid and immunosuppressant exposure, and higher attainment of treatment targets. LO-SLE was associated with higher odds of attaining LLDAS (odds ratio [OR] 2.33, 95% CI 1.66-3.28) and DORIS remission (OR 2.22, 95% CI 1.45-3.38). However, patients in this group were at a greater risk of damage accrual (hazard ratio 1.82, 95% CI 1.50-2.21) and lower PCS scores, meaning poorer physical health (regression coefficient [RC] −3.63, 95% CI −4.58 to −2.68), but not MCS scores (RC 0.68, 95% CI −0.50 to 1.86). Conclusion: Despite higher attainment of treatment targets, patients with LO-SLE experienced greater damage accrual and poorer physical health, suggesting that disease activity targets alone may not fully identify outcome risk in LO-SLE.

  • Open Access

    Evaluation of Candidate Definitions of Severe Refractory Systemic Lupus Erythematosus Using Clinical Outcomes: Real-World Data Exploration Study

    by Rangi Kandane Rathnayake, Vera Golder, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef Lateef, Laniyati Hamijoyo, Chak-Sing Lau, Shirley Chan, Yeong-Jian Jan Wu, et al.

    Background: Emerging advanced therapies are being trialled in patients with severe refractory systemic lupus erythematosus (srSLE), but this state lacks an evidence-based operational definition. We evaluated candidate srSLE definitions to determine which best identifies patients with poor outcomes.Methods: We constructed candidate srSLE definitions using varying thresholds of treatment-refractory disease activity and evaluated the definitions in the Asia Pacific Lupus Collaboration cohort. At each visit (tn), disease activity was defined using SLE Disease Activity Index (SLEDAI-2K ≥6, ≥8, ≥10, or ≥12), Physician Global Assessment (PGA ≥1 or >1), and SELENA-SLEDAI Flare Index (SFI mild-to-moderate and severe flare (MMSf) or severe flares only (Sf)). Treatment refractoriness required concurrent use of immunosuppressants (IS) at tn and tn-1 (preceding visit), together with glucocorticoids (GC, ≥5 or ≥10mg/day prednisolone equivalent), with or without concurrent anti-malarial (AM) use. Outcomes accessed at 12 months after the first visit fulfilling each definition criteria included flare, organ damage accrual (SLICC/ACR Damage Index) and non-attainment of lupus low disease activity state. Candidate definitions were ranked from highest to lowest rates for each outcome. Ten definitions were associated with highest rates across all three outcomes (‘top 10’); they were further evaluated using machine-learning–based gradient boosting models. Findings: We evaluated 80 candidate definitions (least stringent, achieved by 27% of patients, to most stringent, achieved by 1 and/or MMSf, while 4 definitions included exposure to triple therapy (GC+IS+AM). The best predictive performance on all three outcomes at 12-months was srSLE defined as SLEDAI≥6+GC≥10+IS+PGA>1+MMSf, observed in 267 (6.5%) of patients. Interpretation: We derived data-driven definitions of srSLE with strong predictive performance for poor patient outcomes. This may help standardise patient selection for trials of transformative therapies under development.

  • Open Access

    Predictive correlates of arthritis and joint damage in systemic lupus erythematosus: a multinational prospective cohort study

    by Luigi Zolio, Yanjie Hao, Rangi Kandane-Rathnayake, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue Fen Luo, Yeong-Jian Jan Wu, et al.

    Objectives: To determine the prevalence and predictive correlates of arthritis and joint damage in systemic lupus erythematosus (SLE) patients in the Asia-Pacific Lupus Collaboration (APLC) cohort, and to determine their impact on health-related quality of life (HRQoL). Methods: SLE patient data (2013–2020) were collected from the prospective multinational APLC cohort. We defined arthritis according to the SLE Disease Assessment Index (SLEDAI-2K) definition of persistent arthritis as arthritis in ≥2 consecutive visits, and joint damage according to the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) definition (deforming or erosive arthritis). HRQoL was measured by Short Form Survey (SF36). Descriptive statistics, univariable and multivariable Cox hazard models, and Kaplan–Meier analyses were performed. Results: During median 2.5 (1.0–5.1) years of follow-up, 803/4106 (19.6%) patients had arthritis at least once, and 18/3383 (0.53%) accrued joint damage. Patients with arthritis were more likely to be female, Caucasian, current smokers at enrolment, and less like to have tertiary education; they also had higher overall disease activity, and lower physical and mental HRQoL. Kaplan–Meier analysis demonstrated that joint damage was more likely in patients with arthritis. Persistent arthritis and longer follow-up were risk factors for joint damage accrual; being from high-income countries was protective. Patients with joint damage also had worse physical HRQoL. Conclusion: Arthritis in the APLC cohort was infrequent compared with other cohorts and was associated with smoking, higher overall disease activity, and damage accrual across multiple domains. Presence of arthritis significantly impacted physical and mental HRQoL. Joint damage was strongly predicted by persistent arthritis.

  • Open Access

    Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active

    by Yanjie Hao, Dylan Hansen, Rangi Kandane‐Rathnayake, Worawit Louthrenoo, Yi‐Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Jan Wu, et al.

    Objective: This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment. Methods: Patients in a multinational cohort with SLE who had clinical disease activity but were not in LLDAS or DORIS were observed prospectively. Results: A total of 1,991 patients (93.2% female) were observed for a median (interquartile range) of 2.5 (0.7–4.5) years, with 70.9% and 55.6% achieving LLDAS and DORIS, respectively. Nephritis and low complements were associated with a longer time, and antimalarial and immunosuppressant use were associated with a shorter time to LLDAS attainment. After the first LLDAS and DORIS attainment, 47.0% and 47.5% of the patients experienced flare(s), respectively, and 9.5% and 7.9 % of patients accrued organ damage within 24 months, respectively. Longer cumulative time at target and antimalarial use was associated with a longer time to flare and damage accrual, whereas dose reduction in glucocorticoids and immunosuppressants was associated with a shorter time to flare. Reduction in immunosuppressants also correlated with a shorter time to damage accrual. Conclusion: In patients with SLE with clinical disease activity, the proportion attaining LLDAS and DORIS under usual care conditions is suboptimal. Longer maintenance of these states is significantly associated with reduced risk of flare. Because flares and damage accrual still occur frequently following initial target attainment, further research is needed to inform strategies for maintaining these targets.


  • Open Access

    Predictors of damage accrual by organ domain in systemic lupus erythematosus

    by Rangi Kandane-Rathnayake, Luigi Zolio, J Iyoon Choi, Vera Golder, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue-Fen Luo, et al.

    Objectives: Organ damage in SLE is assessed using the SLICC/ACR Damage Index (SDI), which quantifies damage in 12 organ systems but generally reports a total score. We examined whether the risk factors for overall organ damage accrual captured those associated with domain-specific damage accrual in patients with SLE. Methods: Data from a 13-country longitudinal SLE cohort were collected between 2013 and 2020 using standard templates. SDI was used to assess overall and domain-specific organ damage. A series of multi-failure, multivariate models were performed to examine the risk factors associated with overall and domain-specific damage accrual. Results: A total of 3449 patients with a median of 2.8 [interquartile range (IQR): 1.1, 5.6] years of follow-up were studied. Twenty-one percent (n = 717) patients accrued damage in at least one domain during the study period (musculoskeletal, 6%; renal and ocular, 5% each, neuropsychiatric, 2.5%; <2%, other domains). Risk factors for damage accrual differed among domains. Older age, cumulative glucocorticoid dose, existing skin damage, and diabetes were strong predictors in multiple but discrete domains. Asian ethnicity conferred greater risk of ocular, musculoskeletal, and diabetic damage accrual but was protective against peripheral vascular damage accrual. Smoking was a significant risk factor for peripheral vascular and skin damage accrual, while male sex was associated with the malignancy domain. Conclusion: Risk factors for individual organ system damage accrual were highly varied in patients with SLE. Not all factors associated with domain-specific damage accrual were captured by the risk factors analysed for overall organ damage accrual. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03138941.


  • Open Access

    Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort

    by Yanjie Hao, Dylan Hansen, Worawit Louthrenoo, Yi‐Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Wu, Sandra Navarra, et al.

    Objective: In contrast to relapsing‐remitting patterns, persistently active disease (PAD) is a disease activity pattern in patients with systemic lupus erythematosus (SLE) that is inadequately studied. We sought to identify the frequency and determinants of flare and PAD in SLE.Methods: Flare was defined using the Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index (SELENA–SLEDAI flare index), and PAD was defined as an SLEDAI‐2K score of ≥4, excluding serology only, on two or more consecutive visits with a maximum six‐month interval. Multivariable logistic regression was used to develop predictive models for flare and PAD, which were tested in an independent validation subset.Results: Among 3,811 patients over 2.8 (interquartile range 1.0–5.3) years of follow‐up, 2,142 (56.2%) experienced flare and 1,786 (46.9%) had PAD, with 368 (9.7%) experiencing PAD but not flare. The most common flare features were nephritis and arthritis, whereas PAD was most commonly characterized by renal or mucocutaneous activity. After adjusting for prednisone dose and use of antimalarials and immunosuppressants, low gross domestic product in country of residence, smoking, arthritis, nephritis, and low complement levels were predictive for flare, whereas being in a low disease activity state for ≥50% of follow‐up time (LLDAS50) was a protective factor. Renal activity and higher time‐adjusted mean SLEDAI‐2K were predictive of PAD, whereas LLDAS50 was protective. The models developed gave 72.1% and 83.8% correct classification of flare and PAD, respectively, in the validation cohort.Conclusion: Both flare and PAD are common disease activity patterns in SLE; both predict organ damage accrual but differ in disease features and predictive factors. Because 9.7% of patients experience PAD but not flare, flare measures alone do not adequately capture all patients in whom disease control is suboptimal.


  • Open Access

    Time trends of variability in disease activity in systemic lupus erythematosus

    by Ning Li, Alberta Hoi, Shue-Fen Luo, Yeong-Jian Jan Wu, Worawit Louthrenoo, Vera Golder, Sargunan Sockalingam, Jiacai Cho, Aisha Lateef, Sean O’nEill, et al.

    Objective: Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in SLE disease activity over time.Methods: We analysed data from 2930 patients with SLE across 13 countries, collected over 38 754 clinic visits between 2013 and 2020. Clinic visit records were converted to panel data with 1-year intervals. The time-adjusted mean disease activity, termedAMS, was calculated. The yearly change in A M S , denoted as Δ A M S t , was regressed onto A M S t − 1 and other potential predictors using random-effects models. Some variables were split into a person-mean component to assess between-patient differences and a demeaned component to assess within-patient variability.Results: Overall, variability in SLE disease activity exhibited stabilisation over time. A significant inverse relationship emerged between a patient’s disease activity in a given year and variability in disease activity in the subsequent year: a 1-point increase in person-mean disease activity was associated with a 0.27-point decrease (95% CI −0.29 to –0.26, p<0.001) in subsequent variability. Additionally, a 1-point increase in within-patient disease activity variability was associated with a 0.56-point decrease (95% CI −0.57 to –0.55, p<0.001) in the subsequent year. Furthermore, each 1-point increase in the annual average time-adjusted mean Physician Global Assessment was associated with a 0.08-point decrease (90% CI −0.13 to –0.03, p=0.002) in disease activity variability for the following year. Prednisolone dose and the duration of activity in specific organ systems exhibited negative and positive associations, respectively, with disease activity variability in the subsequent year. Patients from less affluent countries displayed greater disease activity variability compared with those from wealthier nations.Conclusion: Disease activity tends to be less variable among patients with higher or more variable disease activity in the previous year. Within-patient variability in disease activity has a stronger impact on subsequent fluctuations than differences between individual patients.


  • Open Access

    Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus

    by Rangi Kandane-Rathnayake, Dominique Milea, Worawit Louthrenoo, Alberta Hoi, Vera Golder, Jiacai Cho, Aisha Lateef, Shue-Fen Luo, Yeong-Jian Jan Wu, Laniyati Hamijoyo, et al.

    Objective: To estimate the prevalence of organ damage (damage) and flare and to examine longitudinal associations between flares and subsequent damage accrual, in patients with systemic lupus erythematosus (SLE).Methods: Patients enrolled in the Asia Pacific Lupus Collaboration cohort with ≥3 years of prospectively captured data were studied. Flares were assessed at routine visits, while damage ((Systemic Lupus International Collaborating Clinics/American College of Rheumatology) Damage Index) was assessed annually. Multivariable, multifailure survival analyses were carried out to quantify the association between flares and damage accrual.Results: 1556 patients with SLE with a median (IQR) of 5.7 (3.9, 7.0) years of follow-up were studied. 39.5% (n=614) of patients had damage at enrolment, and 31.9% (n=496) accrued damage during the study observation period. The incidence of damage accrual during observation was ~58/1000 person-years. Overall, 74.1% (n=1153) of patients experienced a flare of any severity (mild/moderate or severe) at least once; 56.9% (n=885) experienced recurrent (≥2) flares. The risk of subsequent damage accrual in patients who experienced mild-to-moderate flare, after controlling for confounders, was 32% greater than in patients without flares (adjusted HR) (95% CI 1.32 (1.17 to 1.72)). The risk of damage accrual was greater if patients had severe flares (HR (95% CI) 1.58 (1.18 to 2.11)). For each additional flare, the risk of damage accrual increased by 7% (HR (95% CI) 1.07 (1.02 to 1.13)).Conclusions: Flares independently increased the risk of damage accrual. Prevention of flares should be considered a necessary goal of SLE disease management to minimise permanent damage.


  • Open Access

    Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus

    by Yanjie Hao, Dylan Hansen, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue-Fen Luo, Yeong-Jian Jan Wu, Sandra Navarra, et al.

    Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity. Methods Patients with SLE enrolled in a prospective multinational cohort from March 2013 to December 2020 who were in LLDAS at least once were included. Visits that fulfilled both LLDAS and Definition of Remission in SLE (DORIS) criteria were excluded. Results 2099 patients were included, with median follow-up of 3.5 (IQR 1.3–5.8) years. At 6150 visits, patients were in LLDAS but not DORIS criteria; of these 1280 (20.8%) had some clinical activity, 3102 (50.4%) visits had serological activity only and 1768 (28.8%) visits had neither clinical nor serological activity. Multivariable regression analysis showed that compared with non-LLDAS, all three subsets of LLDAS had a protective association with flares in the ensuing 6 months and damage accrual in the ensuing 36 months. LLDAS with no clinical or serological activity had a significantly stronger protective association with severe flares in the ensuing 6 months compared with LLDAS with clinical activity (HR 0.47, 95% CI (0.27 to 0.82), p=0.007). Conclusions LLDAS without any clinical activity accounted for almost 80% of LLDAS visits. This study confirms that all subsets of LLDAS are associated with reduced flare and damage accrual. However, LLDAS without any clinical or serological activity has the strongest protective association with severe flares.